Company Overview and News
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
2018-09-11 seekingalpha - 2
Investors who bought NXP Semiconductors (NXPI) on the expectation that Qualcomm (QCOM) would complete the buyout are now holding the back. While Qualcomm is now thriving in the markets, NXPI stock is languishing. The stock fell around 5 percent when management showed its hand and its greed. By looking out for itself instead of shareholders, NXP will continue underperforming. As markets price in the nearly completed share buyback, the stock could close at $80.
MU AMAT STM WDC AMBA QCOM
Global semiconductor revenues hit a record high in the second quarter of 2018 according to an IHS Markit report. This definitely is good news for chipmakers, as the industry seems to be braving trade war fears with ease. Chip stocks are likely to remain unaffected, as China so far has been targeting the United States with tariffs on commodities that include agricultural goods and industrials, given its current goal of building up its own tech industry.
SOJA STZ.B SO TXN STM VSH STZ MXIM ON
Investors interested in stocks from the Semiconductor - General sector have probably already heard of STMicroelectronics (STM - Free Report) and Nvidia (NVDA - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Investors with an interest in Semiconductor - General stocks have likely encountered both Xcerra (XCRA - Free Report) and STMicroelectronics (STM - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
STM NVR TRN XCRA
Ladies and gentlemen, good morning or good afternoon. Welcome to the Second Quarter 2018 Earnings Release Conference Call and Live Webcast. I'm Moira, the Chorus Call operator. I would like to remind you that all participants will be in listen-only mode and the conference is being recorded. After the presentation, there will be a Q&A session. The conference must not be recorded for publication or broadcast.
STM STM STMEF
2018-07-19 seekingalpha - 1
Autonomous vehicles timeline - GM to launch fully autonomous EV robo-taxis in the US in 2019.
LMT FB SSNLF NFLX NVDA NOC AAPL GM INTC BIDU VLKAY STM SFBTF BC94 MA SMSN BSWQY DDAIF COL SNEJF V GOOGL MU SNE QCOM APTV SMSD
There are always investors who want to take advantage of Apple's (AAPL) success, but they may already have plenty of the stock in their portfolio. The next best thing is usually to purchase key Apple suppliers. Today, I want to examine one of the lesser known names, STMicroelectronics (STM), which may be an interesting opportunity ahead of this year's Apple fall launch cycle.
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
ECOR PLNT PKG AEP NINE ADT GE COF-P GILD TMUS PDYPF SYF XERS JNJ VZ MSFT ADS KZR NNN EIDX FB AVRO HOPE NFLX AXP EHC BAC COF-D SEAS COF-C COF-F KR KS IIIV PNFP AAPL DDOC SJM INPAP SIX JPM GNE WRK LGEJY KMRFZ DE 39IB KMX RF UAL WMT CFIN LGEAF IP AMZN MGTA NTRS HON KMI CIWV HCSG KMR CVB VLKAY LGEIY EBAY EPRT STT SLB BAC DFS LGEPF STM BBY BX BK STM LTXB LGLD SLB FOXA CLW PM NTRSP AUTL DLPH SWKS GS SWK TRTX GM PII DIS NEE IBM MOR F GEC C CMCSA COF FUN FUL CFG HBAN XEL TGT BLK S PPG T SNE DPZ
Investors with an interest in Semiconductor - General stocks have likely encountered both Xcerra (XCRA - Free Report) and STMicroelectronics (STM - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Global semiconductor sales increased 21% in May on a year-over-year basis. This certainly is good news for chipmakers that have been bearing the brunt of President Donald Trump’s trade policies. Trade war fears have been weighing on markets for quite some time and semiconductor stocks, which so long remained unaffected, felt the heat last month after the United States announced tariffs of 25% on semiconductors.
ABX MU STM NVDA INTC XCRA ABX
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to EPA:STM / STMICROELECTRONICS on message board site Silicon Investor.